Modifications and uses of conotoxin peptides
View Patent ↗The present disclosure describes analog conotoxin peptides of the α-conotoxin peptide RgIA. These analog conotoxin peptides block the α9α10 subtype of the nicotinic acetylcholine receptor (nAChR) and can be used for treating pain and inflammation including inflammatory pain, cancer related pain, and neuropathic pain. The RgIA analogs described in the present invention include a variety of sequence modifications and chemical modifications that are introduced to improve the drug-like characteristics of RgIA analogs and thereby increase their therapeutic value.
1. A conotoxin peptide of Formula (I):
wherein the triazole bridge is
wherein each X represents
and
wherein the C-terminus is a carboxylic acid or an amide group;
or a variant thereof that differs from the conotoxin peptide only in having one conservative amino acid substitution, wherein the variant comprises said triazole bridge, said disulfide bridge, and each said X represented by
or a pharmaceutically acceptable salt of the conotoxin peptide or variant.
2. The variant or pharmaceutically acceptable salt of the variant of claim 1 .
3. A PEGylated conotoxin peptide, wherein the PEGylated conotoxin peptide is of Formula (I) covalently attached to one or more polyethylene glycol (PEG) polymers:
wherein the triazole bridge is
wherein each X represents
and
wherein the C-terminus is a carboxylic acid or an amide group;
or a PEGylated variant thereof that differs from the PEGylated conotoxin peptide only in having one conservative amino acid substitution, wherein the PEGylated variant comprises said triazole bridge, said disulfide bridge, each said X represented by
and said one or more covalently attached PEG polymers;
or a pharmaceutically acceptable salt of the PEGylated conotoxin peptide or the PEGylated variant.
4. The PEGylated variant or pharmaceutically acceptable salt of the PEGylated variant of claim 3 .
5. A pharmaceutical composition comprising the conotoxin peptide or variant, or pharmaceutically acceptable salt of the conotoxin peptide or variant, of claim 1 , and a pharmaceutically acceptable carrier.
6. A pharmaceutical composition comprising the variant or pharmaceutically acceptable salt of the variant of claim 2 , and a pharmaceutically acceptable carrier.
7. A pharmaceutical composition comprising the PEGylated conotoxin peptide or PEGylated variant, or pharmaceutically acceptable salt of the PEGylated conotoxin peptide or PEGylated variant, of claim 3 , and a pharmaceutically acceptable carrier.
8. A pharmaceutical composition comprising the PEGylated variant or pharmaceutically acceptable salt of the PEGylated variant of claim 4 , and a pharmaceutically acceptable carrier.
9. A method of treating pain, an inflammatory condition, pain and inflammation, or inflammation and neuropathy comprising administering to a subject in need thereof a therapeutically effective amount of the conotoxin peptide or variant, or pharmaceutically acceptable salt of the conotoxin peptide or variant, of claim 1 .
10. The method of claim 9 , which is a method of treating pain, or pain and inflammation, wherein the pain is general pain, chronic pain, neuropathic pain, nociceptive pain, inflammatory pain, pain induced by peripheral nerve damage, pain induced by an inflammatory disorder, pain induced by a metabolic disorder, pain induced by cancer, pain induced by chemotherapy, pain induced by a surgical procedure, and/or pain induced by a burn.
11. The method of claim 9 , which is a method of treating an inflammatory condition, wherein the inflammatory condition is inflammation, chronic inflammation, a rheumatic disease, sepsis, fibromyalgia, inflammatory bowel disease, sarcoidosis, endometriosis, uterine fibroids, an inflammatory skin disease, an inflammatory condition of the lungs, a disease associated with inflammation of the nervous system, periodontal disease, or cardiovascular disease.
12. A method of treating pain, an inflammatory condition, pain and inflammation, or inflammation and neuropathy comprising administering to a subject in need thereof a therapeutically effective amount of the variant or pharmaceutically acceptable salt of the variant of claim 2 .
13. The method of claim 12 , which is a method of treating pain, or pain and inflammation, wherein the pain is general pain, chronic pain, neuropathic pain, nociceptive pain, inflammatory pain, pain induced by peripheral nerve damage, pain induced by an inflammatory disorder, pain induced by a metabolic disorder, pain induced by cancer, pain induced by chemotherapy, pain induced by a surgical procedure, and/or pain induced by a burn.
14. The method of claim 12 , which is a method of treating an inflammatory condition, wherein the inflammatory condition is inflammation, chronic inflammation, a rheumatic disease, sepsis, fibromyalgia, inflammatory bowel disease, sarcoidosis, endometriosis, uterine fibroids, an inflammatory skin disease, an inflammatory condition of the lungs, a disease associated with inflammation of the nervous system, periodontal disease, or cardiovascular disease.
15. A method of treating pain, an inflammatory condition, pain and inflammation, or inflammation and neuropathy comprising administering to a subject in need thereof a therapeutically effective amount of the PEGylated conotoxin peptide or PEGylated variant, or pharmaceutically acceptable salt of the PEGylated conotoxin peptide or PEGylated variant, of claim 3 .
16. The method of claim 15 , which is a method of treating pain, or pain and inflammation, wherein the pain is general pain, chronic pain, neuropathic pain, nociceptive pain, inflammatory pain, pain induced by peripheral nerve damage, pain induced by an inflammatory disorder, pain induced by a metabolic disorder, pain induced by cancer, pain induced by chemotherapy, pain induced by a surgical procedure, and/or pain induced by a burn.
17. The method of claim 15 , which is a method of treating an inflammatory condition, wherein the inflammatory condition is inflammation, chronic inflammation, a rheumatic disease, sepsis, fibromyalgia, inflammatory bowel disease, sarcoidosis, endometriosis, uterine fibroids, an inflammatory skin disease, an inflammatory condition of the lungs, a disease associated with inflammation of the nervous system, periodontal disease, or cardiovascular disease.
18. A method of treating pain, an inflammatory condition, pain and inflammation, or inflammation and neuropathy comprising administering to a subject in need thereof a therapeutically effective amount of the PEGylated variant or pharmaceutically acceptable salt of the PEGylated variant of claim 4 .
19. The method of claim 18 , which is a method of treating pain, or pain and inflammation, wherein the pain is general pain, chronic pain, neuropathic pain, nociceptive pain, inflammatory pain, pain induced by peripheral nerve damage, pain induced by an inflammatory disorder, pain induced by a metabolic disorder, pain induced by cancer, pain induced by chemotherapy, pain induced by a surgical procedure, and/or pain induced by a burn.
20. The method of claim 18 , which is a method of treating an inflammatory condition, wherein the inflammatory condition is inflammation, chronic inflammation, a rheumatic disease, sepsis, fibromyalgia, inflammatory bowel disease, sarcoidosis, endometriosis, uterine fibroids, an inflammatory skin disease, an inflammatory condition of the lungs, a disease associated with inflammation of the nervous system, periodontal disease, or cardiovascular disease.